untitled
<OAI-PMH schemaLocation=http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd>
<responseDate>2018-01-15T18:28:28Z</responseDate>
<request identifier=oai:HAL:hal-01175528v1 verb=GetRecord metadataPrefix=oai_dc>http://api.archives-ouvertes.fr/oai/hal/</request>
<GetRecord>
<record>
<header>
<identifier>oai:HAL:hal-01175528v1</identifier>
<datestamp>2018-01-11</datestamp>
<setSpec>type:ART</setSpec>
<setSpec>subject:sdv</setSpec>
<setSpec>collection:UNIV-RENNES1</setSpec>
<setSpec>collection:CNRS</setSpec>
<setSpec>collection:UNIV-AG</setSpec>
<setSpec>collection:IRSET</setSpec>
<setSpec>collection:HL</setSpec>
<setSpec>collection:IRSET-HIAEC</setSpec>
<setSpec>collection:IFR140</setSpec>
<setSpec>collection:BIOSIT</setSpec>
<setSpec>collection:UR1-UFR-SVE</setSpec>
<setSpec>collection:STATS-UR1</setSpec>
<setSpec>collection:UR1-HAL</setSpec>
<setSpec>collection:EHESP</setSpec>
<setSpec>collection:USPC</setSpec>
<setSpec>collection:UR1-SDV</setSpec>
<setSpec>collection:IRSET-2</setSpec>
<setSpec>collection:UNIV-ANGERS</setSpec>
<setSpec>collection:UNIV-MONTPELLIER</setSpec>
</header>
<metadata><dc>
<publisher>HAL CCSD</publisher>
<title lang=en>Leishmania-RNA virus presence in L. guyanensis parasites increases the risk of first-line treatment failure and symptomatic relapse</title>
<creator>Bourreau, Eliane</creator>
<creator>Ginouves, Marine</creator>
<creator>Prévot, Ghislaine</creator>
<creator>Hartley, Mary-Anne</creator>
<creator>Gangneux, Jean-Pierre</creator>
<creator>Robert-Gangneux, Florence</creator>
<creator>Dufour, Julie</creator>
<creator>Sainte, Marie-Dominique</creator>
<creator>Bertolotti, Antoine</creator>
<creator>Pratlong, Francine</creator>
<creator>Martin, Ricardo</creator>
<creator>Schütz, Frédéric</creator>
<creator>Couppié, Pierre</creator>
<creator>Fasel, Nicolas</creator>
<creator>Ronet, Catherine</creator>
<contributor>Institut Pasteur de la Guyane</contributor>
<contributor>Institut de recherche, santé, environnement et travail [Rennes] (Irset) ; Université d'Angers (UA) - Université des Antilles et de la Guyane (UAG) - Université de Rennes 1 (UR1) - École des Hautes Études en Santé Publique [EHESP] (EHESP) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )</contributor>
<contributor>Service de Parasitologie-Mycologie [Rennes] ; Université de Rennes 1 (UR1) - Hôpital Pontchaillou - CHU Pontchaillou [Rennes]</contributor>
<contributor>Service de Dermatologie et Vénérologie ; Centre Hospitalier de Cayenne Andrée Rosemon</contributor>
<contributor>Laboratoire de Parasitologie-Mycologie, Montpellier (MIVEGEC) ; Centre National de la Recherche Scientifique (CNRS) - Institut de recherche pour le développement [IRD] : UR224 - Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier) - Université Montpellier 2 - Sciences et Techniques (UM2) - Université Montpellier 1 (UM1) - Université de Montpellier (UM)</contributor>
<contributor>Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)</contributor>
<contributor>Center for Integrative Genomics - Institute of Bioinformatics, Génopode (CIG) ; University of Lausanne</contributor>
<contributor>SIB Swiss Institute of Bioinformatics</contributor>
<contributor>Department of Biochemistry (WHO-IRTC) ; Université de Lausanne (UNIL)</contributor>
<description>International audience</description>
<source>Journal of Infectious Diseases</source>
<identifier>hal-01175528</identifier>
<identifier>https://hal-univ-rennes1.archives-ouvertes.fr/hal-01175528</identifier>
<source>https://hal-univ-rennes1.archives-ouvertes.fr/hal-01175528</source>
<source>Journal of Infectious Diseases, 2016, 213 (1), pp.105-111. 〈10.1093/infdis/jiv355〉</source>
<identifier>DOI : 10.1093/infdis/jiv355</identifier>
<relation>info:eu-repo/semantics/altIdentifier/doi/10.1093/infdis/jiv355</relation>
<identifier>PUBMED : 26123564</identifier>
<relation>info:eu-repo/semantics/altIdentifier/pmid/26123564</relation>
<language>en</language>
<subject lang=en> pentamidine </subject>
<subject lang=en> mutualism exclusive </subject>
<subject lang=en>leishmaniasis L.</subject>
<subject lang=en> guyanensis</subject>
<subject lang=en> Leishmania RNA virus</subject>
<subject lang=en> drug treatment</subject>
<subject>[SDV] Life Sciences [q-bio]</subject>
<type>info:eu-repo/semantics/article</type>
<type>Journal articles</type>
<description lang=en>Treatment failure and symptomatic relapse are major concerns in American tegumentary leishmaniasis (ATL). Such complications are seen frequently in L.guyanensis infections where patients respond variously to first-line anti-leishmanials and are more prone to develop chronic cutaneous leishmaniasis. The factors underlying this pathology, however, are unknown. Recently ,: we reported that a dsRNA virus (LRV1) nested within L.guyanensis parasites is able to exacerbate experimental murine leishmaniasis by inducing a hyper-inflammatory response. This report investigates the prevalence of LRV1 in human L.guyanensis infection and its effect on treatment efficacy as well as its correlation to symptomatic relapses after the first-line treatment. In our cohort of 75 patients diagnosed with primary-localised ATL, the prevalence of LRV1+ infection was elevated to 58%. All patients infected with LRV1-negative L.guyanensis were cured after one (22/31 i.e.71%) or two (31/31 i.e.100%) doses of pentamidine. Oppositely, 12 out of the 44 LRV1-positive patients presented with persistent infection and symptomatic relapse required extended therapy and the use of second-line drugs. Finally, LRV1 presence was associated with a significant increase in intra-lesional inflammatory markers. In conclusion, LRV1 status in L.guyanensis infection is significantly predictive (p=0.0009) of first-line treatment failure and symptomatic relapse, and could stand to guide therapeutic choices in ATL</description>
<date>2016</date>
</dc>
</metadata>
</record>
</GetRecord>
</OAI-PMH>
